This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

PDL BioPharma Inc. (PDLI)

NASDAQ: Health Care

Get a 5-page Ratings Report on (PDLI) now
$8.250.08 | 0.98%
04/16/14 - 4:00 PM ET
Company Profile
Price and Volume
Recent Price 8.17
52 Week High 10.21
52 Week Low 7.38
Avg. Daily Vol. (Mil) 3.40
Beta (3 year) 0.52
Share Related Items
Mkt Cap (Mil) 1,310.08
Shares Out (Mil) 160.35
Float (Mil) 121.97
Dividend Information
Yield % 7.30
Annual Dividend 0.60
Payout Ratio 36.00
Financial Strength
Quick Ratio 0.20
Current Ratio 0.30
LT Debt/ Equity 0.00
Total Debt / Equity 3.48
Valuation Ratios
Price Earnings 4.90
Price/Sales 2.96
Price/Book 11.54
Price/Cash Flow 4.60
Per Share Data
Earnings 1.66
Sales 2.76
Book Value 0.71
Cash Flow 1.77
Business Summary
PDL BioPharma, Inc., is engaged in the discovery of a new generation of targeted treatments for cancer & immunologic diseases. It focuses on intellectual property asset management, investing in new royalty bearing assets & maximizing value of its patent.
General Information
932 Southwood Boulevard
Incline Villiage, NV 89451
www.pdl.com
Industry : Drugs
Sector: Health Care
Employees: 10
CEO: Mr. John P. Mclaughlin
Short Interest
Current Month (Mil) 25.70
Previous Month (Mil) 26.77
Short Interest Ratio (Days) 6.80
Management Effectiveness
Return on Equity 233.10
Return on Assets 48.60
Return on Investments 233.10
Profitability
Gross Margin 98.70
EBIT Margin 92.20
Profit Margin 59.70
(PDLI) News

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,424.85 +162.29 1.00%
S&P 500 1,862.31 +19.33 1.05%
NASDAQ 4,086.2250 +52.0640 1.29%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs